Innovating Works

ATLAS

Financiado
Next generation HPC/QC in silico drug discovery platform for de novo design
ATLAS is a powerful in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing. The platform is the result of decades of research by leading experts in molecular dynamics. The techno... ATLAS is a powerful in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing. The platform is the result of decades of research by leading experts in molecular dynamics. The technology is grounded on over 100 peer-reviewed papers and two ERC grants. Our beta code has gathered important accolades like the prestigious ATOS-Joseph Fourier prize and first place at the foremost rational drug design competition—the SAMPL challenge. ATLAS can replace costly and laborious experiments. It can even run entire drug discovery campaigns in silico, reducing cycle times and cost by at least 50%. By 2027, we will have a 35-project portfolio, and the first ATLAS-generated compound will reach the clinic. Thereafter, our objective is to generate a new candidate every 18 months. That year, our team will surpass 50 people and we’ll expand into the US market. We aim at securing a leadership position in the nascent in-silico drug discovery market. ver más
31/08/2024
QUBIT
4M€
Perfil tecnológico estimado
Duración del proyecto: 25 meses Fecha Inicio: 2022-07-28
Fecha Fin: 2024-08-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01: Strategic Digital and Health Technologies
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
QUBIT PHARMACEUTICALS No se ha especificado una descripción o un objeto social para esta compañía.